Booster do work

Booster doses probably needed by most people, unfortunately.Uploaded 04-11-21https://ourworldindata.org/covid-vaccinationshttps://covid.cdc.gov/covid-data-tracker/#covidnet-hospitalizations-vaccinationUS, 20.6 million so farhttps://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.htmlSix months after 2nd shot65 years and older50–64 years with underlying medical conditions18 – 64 years, working / living in high-risk settings18 years and older, 2 months Johnson and Johnson/JanssenProtection of BNT162b2 Vaccine Booster against Covid-19 in Israel (NEJM, October 2021)https://www.medrxiv.org/content/10.1101/2021.08.27.21262679v1https://www.nejm.org/doi/full/10.1056/NEJMoa2114255?July 30, 2021, over 602Third (booster) dose of the Pfizer BNT162b2 vaccine was approved60 years or older who had been fully vaccinatedAugust 29th, anyone over 12At least five months previouslyN = 1,144,6902 dynamic cohorts2 vaccines onlyN = 5.2 million person days4,439 confirmed infections294 cases of severe covid(based on 4.6 million person days)2 vaccines + boosterN = 10.6 million person days934 confirmed infections29 cases of severe COVID-19(based on 6.3 million person days)(despite older demographic)Twelve days or more after the booster doseIncreases antibody neutralization levels ~10-fold compared to after 2nd dose11.3 fold decrease in the relative risk of confirmed infectionEfficacy among booster recipients to approximately 95%(May have waned to 50% with time and delta variant)https://www.medrxiv.org/content/10.1101/2021.08.24.21262423v119.5 fold decrease in the relative risk of severe illnessFactor reduction in reduced rate of confirmed infection in boosted versus none-boostedIn conjunction with safety reportsthis study demonstrates the effectiveness of a third vaccine dose,in both reducing transmission and severe disease,indicates the great potential of curtailing the Delta variant resurgence by administering booster shotsDecline in immunity, UK datahttps://www.gov.uk/government/news/over-eight-million-people-in-the-uk-receive-covid-19-booster-jabsProtection against symptomatic disease, Oxford/AstraZeneca vaccine 65%, up to 3 months after the second dose45% 6 months after the second doseProtection against symptomatic disease, Pfizer/BioNTech vaccine90% up to 3 months after 2nd dose65% 6 months after the second doseProtection against hospitalisation, Oxford/AstraZeneca vaccine 95% at 3 months75% at 6 months Protection against hospitalisation, Pfizer/BioNTech99% at 3 months9